MRK•benzinga•June 12, 2025 at 10:47 AM

Merck Has Initiated MOBILIZE-1 Phase 3 Trial For Single Dose Of V181, An Investigational Quadrivalent Vaccine, For The Prevention Of Dengue Disease Caused By Any Of The Four Dengue Virus Serotypes. Recruitment For The Trial Has Begun, And The First Partic

No summary available.

Read the full article from the original source for complete details and context.

Article published on June 12, 2025 by benzinga